MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation
Source: SeekingAlpha
2025-08-07 03:46:04 ET
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
- MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
- MaxCyte signs platform license agreement with Adicet Bio
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
5.77% G/L:
$1.10 Last:
1,382,133 Volume:
$1.04 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
